---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020785"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T13:21:15.332881+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella

## Summary
- On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.
- Issued 989,876 shares of common stock to former Nexcella stockholders (including third-party cash investors).
- Issued 275,759 restricted stock awards and options to purchase 595,676 shares at $2.47 per share to former Nexcella equity plan participants.
- Nexcella stockholders have appraisal rights under Delaware law if they perfect them.

## SEC filing metadata
- accession: 0001493152-24-020785
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315224020785/0001493152-24-020785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315224020785/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020785
- JSON: https://secwatch.observer/filing/0001493152-24-020785.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.